Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Feb 08, 2021 11:12am
170 Views
Post# 32500629

RE:RE:RE:THTX for retail investors

RE:RE:RE:THTX for retail investorsI believe everyone should consider  their exit plan based on their overall wealth, risk tolerance and size of their positions in their portfolio.
I personally will assess my exit plan for THTX based on the results of their progresses, if results are promising whether it's oncology early results or NASH getting fast track, breakthrough, priority review or accelerated approval designations I will stay put because in my opinion the market opportunities for those indications are great putting it mildly also those opportunities have not been ascribed to the company's current valuation.
Unless the SP rise significantly probably even higher than your highest predictions on the back of good early results I might consider to sell a portion of my heavily overweight position and keep a rather smaller position as a long term investment but that is just my exit plan.


<< Previous
Bullboard Posts
Next >>